Developer docs
API playgroundTry for free, no card

Search company profiles

Regenesome

Full company profile

uuid0002273

Namestring
Regenesome
Legal namestring
リジェネソーム株式会社
Websiteurl
regenesome.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Regenesome Inc. (リジェネソーム株式会社) is a Tokyo-based longevity biotechnology venture founded on July 12, 2024, as a wholly-owned subsidiary of Space Seed Holdings Co., Ltd. The company develops anti-aging biotechnologies built around exosome analysis, nanoparticle engineering, and hypoxic environment research, with stated ambitions to contribute to lunar habitation by 2040. Its product pipeline includes Vicell, a nanoparticle-based supplement designed for intranasal and oral brain delivery; SakeSome, sake-derived 1-500nm nanoparticles shown to activate B and T cells; and a broader line of exosome-based supplements, foods, and cosmetics. A second technology track targets gene therapy manufacturing via a co-developed ergothioneine-based method for enhancing AAV viral vector productivity.

The company's underlying platform integrates molecular biology, fermentation-derived nanotechnology, and epigenetic clock measurement into a multi-domain intervention framework. Research collaborations underpin the technology base: joint work with Tokyo University of Science produced the sake-nanoparticle immunology patent; a Tohoku University affiliation supports mitochondrial activation research via hypoxic environments; and a partnership with University of Tokyo neurotech startup FastNeura (announced March 2026) extends the platform into EEG-measured cognitive assessment for office wellness applications. Two pending joint patents, one with Good Hero Therapeutics and Euglena Co. and one with Tokyo University of Science, anchor the IP position, though neither has yet been granted.

Regenesome operates as a B2B research-driven venture with three theoretical revenue streams: commercialization of exosome-based consumer products, licensing of longevity-related IP, and consulting services for management, sales, and R&D operations. Pricing is not publicly disclosed and no customer logos or revenue figures are available. Go-to-market is sales-led through research collaborations and co-development agreements rather than direct enterprise sales, and the company has raised approximately $666K across two small seed rounds (Japan System Techniques in October 2024 and Leave a Nest Capital in September 2025) in addition to parent company funding.

Short descriptiontext

Regenesome is a Tokyo-based longevity biotech venture developing exosome-based supplements, sake-derived nanoparticle immune activators, and AAV viral vector manufacturing technologies through B2B research collaborations and joint patent filings with academic and industry partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
exosome biotechnology, nanoparticle supplements, longevity therapeutics, anti-aging research, gene therapy manufacturing
Industry2 codes
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Longevity Biotechnology
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Exosome-based Products
TypeSubscription Recurring
Description

Development and potential commercialization of supplements, foods, and cosmetics utilizing exosomes. Also includes development of new products and services utilizing substances contained in other cells.

regenesome.com
2Licensing and IP Management
TypeLicensing Royalties
Description

Intellectual property management including patents for virus vector production enhancement, immune cell activation, and other longevity-related technologies.

regenesome.com
3Consulting Services
TypeProfessional Services
Description

Consulting services for management, sales, research and development operations related to longevity and anti-aging biotechnology.

regenesome.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Regenesome (リジェネソーム株式会社) is a longevity biotechnology venture that develops exosome-based supplements, foods, and cosmetics for anti-aging applications, combined with proprietary nanoparticle technology (Vicell for brain-targeted delivery, sake-derived nanoparticles for immune cell activation) and hypoxic environment technology. The company also conducts research into viral vector productivity enhancement for gene therapy manufacturing and offers consulting and intellectual property management services in longevity biotechnology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Improved viral titers after 72 hours of culture with ergothioneine addition compared to control groups
+1 more record
Product overview1 text field

Regenesome is a longevity biotech venture developing a portfolio of nanoparticle-based health products. The core offering centers on exosome-based supplements, foods, and cosmetics targeting anti-aging and healthspan extension. Key product lines include Vicell (brain-targeting nanoparticle supplements for cognitive and longevity applications) and SakeSome (Japanese sake-derived nanoparticle immune cell activators). The company combines these products with hypoxic environment technology and epigenetic clock measurement to build a personalized multi-domain intervention platform. All products are developed through the company's molecular biology and nanotechnology capabilities.

Product and service5 records
1Vicell
CategoryLongevity Supplements
Description

Nanoparticle-based supplement technology designed for brain delivery via nasal and oral administration, used in combination with hypoxic environment technology and epigenetic clocks for personalized multi-domain interventions targeting cognitive function and longevity.

2SakeSome (Sake-derived Nanoparticle Ingredient)
CategoryImmune Cell Activation Ingredient
Description

Japanese sake-derived nanoparticle ingredient (1-500nm diameter) containing sugar-protein aggregates from yeast and koji mold, developed through parallel secondary fermentation. Confirmed to activate immune cells (B cells and T cells) and intended for application in regenerative medicine and immune maintenance.

3Exosome-based supplements, foods, and cosmetics
CategoryExosome-based Health Products
Description

Products utilizing exosomes (extracellular vesicles) for anti-aging, regenerative medicine solutions, and longevity applications, developed through detailed exosome analysis and molecular nanotechnology design.

4Ergothioneine-based Virus Vector Productivity Enhancement Technology
CategoryGene Therapy Manufacturing Technology
Description

Technology that enhances virus vector productivity by adding the antioxidant amino acid ergothioneine to cell culture systems, with demonstrated improved viral titers after 72 hours of culture compared to control groups. Developed for gene therapy manufacturing applications.

5Hypoxic Environment Cognitive Assessment Technology
CategoryCognitive Assessment Technology
Description

Scientific evaluation of hypoxic environments on cognitive function through EEG measurements, analyzing brain wave signal fluctuations and task accuracy changes during cognitive N-back tasks under normoxic and hypoxic conditions. Designed for application in office wellness programs and personalized multi-domain intervention platforms.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-25
Description

Neurotech startup from University of Tokyo's Faculty of Medicine conducting collaborative research on the effects of hypoxic environments on cognitive function through EEG measurements. Research involves cognitive N-back tasks under normoxic and hypoxic conditions using Open BCI Cyton Board devices. Aims to apply findings to office wellness programs and develop personalized multi-domain intervention platforms.

2Good Hero Therapeutics Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Gene therapy company with innovative foundational technologies in the field. Joint patent application filed for ergothioneine-based virus vector productivity enhancement technology. Regenesome supports GHT's development of gene therapeutic manufacturing processes using the patented technology. GHT has been selected for national support programs.

prtimes.jp
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Biotechnology company providing candidate substances with potential for improving AAV vector production. Participated in joint patent application for ergothioneine-based virus vector productivity enhancement technology alongside Regenesome and Good Hero Therapeutics.

4Tokyo University of Science (東京科学大学)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-26
Description

National university with International Center for Biomedical Engineering Research. Joint research with Regenesome discovered immune cell activation functions in sake-derived nanoparticles. Resulted in patent application for immune cell activators and activation methods using 1-500nm nanoparticles containing sugar-protein aggregates from yeast and koji mold.

regenesome.com
Strategic tierFlagshipTypeOthers
Description

Parent company of Regenesome. Participates in Space Food Sphere project exploring new possibilities of space food (since April 2024) and XPRIZE Healthspan global competition focused on extending human healthspan (since May 2024). Provides research network and deep knowledge in space and life sciences.

6Tohoku University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership for multifaceted research including mitochondrial activation through hypoxic environments. Regenesome's CEO Kengo Suzuki serves as Visiting Professor at Tohoku University Graduate Program for Frontier Medical Sciences.

regenesome.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Japanese microalgae-based biotech co-founded by Regenesome's CEO Kengo Suzuki in 2005. Operates in health foods, cosmetics, and biofuel — a direct comparable for a Japan-anchored, founder-led biotech commercializing biologically derived health products to consumer markets.

TypeBroad incumbent
Description

US-based longevity supplement company founded by MIT scientists, commercializing NAD+ and other cellular health products. Comparable in the consumer longevity supplement space and in its emphasis on scientific legitimacy for aging interventions.

TypeEmerging player
Description

Well-capitalized (~$3B raised) longevity biotech pursuing cellular rejuvenation programming. Relevant peer in the longevity biotech category and in its pursuit of epigenetic and cellular reprogramming approaches to healthspan extension.

TypeEmerging player
Description

AI-driven longevity and drug discovery biotech with a pipeline of aging-related therapeutics. Comparable in pursuing technology-enabled longevity interventions, though focused on pharmaceutical rather than consumer delivery formats.

5Turn Biotechnologies
TypeEmerging player
Description

US-based cellular rejuvenation company developing mRNA-based epigenetic reprogramming therapies. Directly comparable technology platform (epigenetic reprogramming) and overlap with regenerative medicine and exosome-adjacent delivery science.

TypeEmerging player
Description

South Korea-based exosome therapeutics and cosmetic company. Closest direct peer in commercializing exosome-derived products for regenerative and cosmetic applications in the Asian market.

TypeEmerging player
Description

Veterinary longevity biotech developing drugs to extend dog healthspan, with FDA engagement. Comparable in its science-driven, regulator-engaged approach to commercializing longevity interventions, though in the veterinary category.

TypeBroad incumbent
Description

Alphabet-backed longevity research company pursuing fundamental biology of aging. Relevant as a well-resourced industry incumbent in the broader longevity R&D category, though operating at much larger scale.

TypeBroad incumbent
Description

Publicly listed senescence-focused longevity biotech developing therapeutics targeting aging cells. Comparable in cellular senescence / aging biology focus, though at a far more advanced clinical stage.

10Good Hero Therapeutics
TypeOthers
Description

Tokyo-based gene therapy company and direct joint patent partner with Regenesome on ergothioneine-based AAV productivity enhancement. Closely tied via co-developed IP and capital/business alliance, making it a meaningful ecosystem participant rather than a competitor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Regenesome

Longevity Biotechnologyregenesome.com

Regenesome is a Tokyo-based longevity biotech venture developing exosome-based supplements, sake-derived nanoparticle immune activators, and AAV viral vector manufacturing technologies through B2B research collaborations and joint patent filings with academic and industry partners.

What Regenesome does

Regenesome Inc. (リジェネソーム株式会社) is a Tokyo-based longevity biotechnology venture founded on July 12, 2024, as a wholly-owned subsidiary of Space Seed Holdings Co., Ltd. The company develops anti-aging biotechnologies built around exosome analysis, nanoparticle engineering, and hypoxic environment research, with stated ambitions to contribute to lunar habitation by 2040. Its product pipeline includes Vicell, a nanoparticle-based supplement designed for intranasal and oral brain delivery; SakeSome, sake-derived 1-500nm nanoparticles shown to activate B and T cells; and a broader line of exosome-based supplements, foods, and cosmetics. A second technology track targets gene therapy manufacturing via a co-developed ergothioneine-based method for enhancing AAV viral vector productivity.

The company's underlying platform integrates molecular biology, fermentation-derived nanotechnology, and epigenetic clock measurement into a multi-domain intervention framework. Research collaborations underpin the technology base: joint work with Tokyo University of Science produced the sake-nanoparticle immunology patent; a Tohoku University affiliation supports mitochondrial activation research via hypoxic environments; and a partnership with University of Tokyo neurotech startup FastNeura (announced March 2026) extends the platform into EEG-measured cognitive assessment for office wellness applications. Two pending joint patents, one with Good Hero Therapeutics and Euglena Co. and one with Tokyo University of Science, anchor the IP position, though neither has yet been granted.

Regenesome operates as a B2B research-driven venture with three theoretical revenue streams: commercialization of exosome-based consumer products, licensing of longevity-related IP, and consulting services for management, sales, and R&D operations. Pricing is not publicly disclosed and no customer logos or revenue figures are available. Go-to-market is sales-led through research collaborations and co-development agreements rather than direct enterprise sales, and the company has raised approximately $666K across two small seed rounds (Japan System Techniques in October 2024 and Leave a Nest Capital in September 2025) in addition to parent company funding.

Regenesome firmographics

Firmographics
Name
Regenesome
Legal name
リジェネソーム株式会社
Website
https://regenesome.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Regenesome is a Tokyo-based longevity biotech venture developing exosome-based supplements, sake-derived nanoparticle immune activators, and AAV viral vector manufacturing technologies through B2B research collaborations and joint patent filings with academic and industry partners.
Ownership category
akta.pro rank

Regenesome industry classification

Industry
Product category
Longevity Biotechnology
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Exosome biotechnology
  • Nanoparticle supplements
  • Longevity therapeutics
  • Anti-aging research
  • Gene therapy manufacturing

Where Regenesome is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

Regenesome business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Exosome-based Products: Development and potential commercialization of supplements, foods, and cosmetics utilizing exosomes. Also includes development of new products and services utilizing substances contained in other cells.
  2. Licensing and IP Management: Intellectual property management including patents for virus vector production enhancement, immune cell activation, and other longevity-related technologies.
  3. Consulting Services: Consulting services for management, sales, research and development operations related to longevity and anti-aging biotechnology.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Regenesome product offering

Product offering

Core offering

Regenesome (リジェネソーム株式会社) is a longevity biotechnology venture that develops exosome-based supplements, foods, and cosmetics for anti-aging applications, combined with proprietary nanoparticle technology (Vicell for brain-targeted delivery, sake-derived nanoparticles for immune cell activation) and hypoxic environment technology. The company also conducts research into viral vector productivity enhancement for gene therapy manufacturing and offers consulting and intellectual property management services in longevity biotechnology.

Product overview

Regenesome is a longevity biotech venture developing a portfolio of nanoparticle-based health products. The core offering centers on exosome-based supplements, foods, and cosmetics targeting anti-aging and healthspan extension. Key product lines include Vicell (brain-targeting nanoparticle supplements for cognitive and longevity applications) and SakeSome (Japanese sake-derived nanoparticle immune cell activators). The company combines these products with hypoxic environment technology and epigenetic clock measurement to build a personalized multi-domain intervention platform. All products are developed through the company's molecular biology and nanotechnology capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vicell Nanoparticle-based supplement technology designed for brain delivery via nasal and oral administration, used in combination with hypoxic environment technology and epigenetic clocks for personalized multi-domain interventions targeting cognitive function and longevity.
  • SakeSome (Sake-derived Nanoparticle Ingredient) Japanese sake-derived nanoparticle ingredient (1-500nm diameter) containing sugar-protein aggregates from yeast and koji mold, developed through parallel secondary fermentation. Confirmed to activate immune cells (B cells and T cells) and intended for application in regenerative medicine and immune maintenance.
  • Exosome-based supplements, foods, and cosmetics Products utilizing exosomes (extracellular vesicles) for anti-aging, regenerative medicine solutions, and longevity applications, developed through detailed exosome analysis and molecular nanotechnology design.
  • Ergothioneine-based Virus Vector Productivity Enhancement Technology Technology that enhances virus vector productivity by adding the antioxidant amino acid ergothioneine to cell culture systems, with demonstrated improved viral titers after 72 hours of culture compared to control groups. Developed for gene therapy manufacturing applications.
  • Hypoxic Environment Cognitive Assessment Technology Scientific evaluation of hypoxic environments on cognitive function through EEG measurements, analyzing brain wave signal fluctuations and task accuracy changes during cognitive N-back tasks under normoxic and hypoxic conditions. Designed for application in office wellness programs and personalized multi-domain intervention platforms.

Quantifiable outcome

  • Improved viral titers after 72 hours of culture with ergothioneine addition compared to control groups
  • +1 more outcomes

Companies that use Regenesome

Customer profile

Segments3 records

Ideal customer profiles3 records

Regenesome technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Regenesome partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • FastNeura Inc.coreStrategic or Co-development Partner · 25 March 2026Neurotech startup from University of Tokyo's Faculty of Medicine conducting collaborative research on the effects of hypoxic environments on cognitive function through EEG measurements. Research involves cognitive N-back tasks under normoxic and hypoxic conditions using Open BCI Cyton Board devices. Aims to apply findings to office wellness programs and develop personalized multi-domain intervention platforms.
  • Good Hero Therapeutics Inc.coreStrategic or Co-development Partner · 23 March 2026Gene therapy company with innovative foundational technologies in the field. Joint patent application filed for ergothioneine-based virus vector productivity enhancement technology. Regenesome supports GHT's development of gene therapeutic manufacturing processes using the patented technology. GHT has been selected for national support programs.
  • Euglena Co., Ltd.coreStrategic or Co-development Partner · 23 March 2026Biotechnology company providing candidate substances with potential for improving AAV vector production. Participated in joint patent application for ergothioneine-based virus vector productivity enhancement technology alongside Regenesome and Good Hero Therapeutics.
  • Tokyo University of Science (東京科学大学)coreStrategic or Co-development Partner · 26 December 2025National university with International Center for Biomedical Engineering Research. Joint research with Regenesome discovered immune cell activation functions in sake-derived nanoparticles. Resulted in patent application for immune cell activators and activation methods using 1-500nm nanoparticles containing sugar-protein aggregates from yeast and koji mold.
  • Space Seed Holdings Co., Ltd.flagshipOthersParent company of Regenesome. Participates in Space Food Sphere project exploring new possibilities of space food (since April 2024) and XPRIZE Healthspan global competition focused on extending human healthspan (since May 2024). Provides research network and deep knowledge in space and life sciences.
  • Tohoku UniversitycoreStrategic or Co-development PartnerAcademic partnership for multifaceted research including mitochondrial activation through hypoxic environments. Regenesome's CEO Kengo Suzuki serves as Visiting Professor at Tohoku University Graduate Program for Frontier Medical Sciences.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Regenesome competitors and assessment

Company assessment

Direct peers

  • Euglena Co., Ltd. Japanese microalgae-based biotech co-founded by Regenesome's CEO Kengo Suzuki in 2005. Operates in health foods, cosmetics, and biofuel — a direct comparable for a Japan-anchored, founder-led biotech commercializing biologically derived health products to consumer markets.

Broad incumbents

  • Elysium Health: US-based longevity supplement company founded by MIT scientists, commercializing NAD+ and other cellular health products. Comparable in the consumer longevity supplement space and in its emphasis on scientific legitimacy for aging interventions.
  • Calico Life Sciences: Alphabet-backed longevity research company pursuing fundamental biology of aging. Relevant as a well-resourced industry incumbent in the broader longevity R&D category, though operating at much larger scale.
  • Unity Biotechnology: Publicly listed senescence-focused longevity biotech developing therapeutics targeting aging cells. Comparable in cellular senescence / aging biology focus, though at a far more advanced clinical stage.

Emerging players

  • Altos Labs: Well-capitalized (~$3B raised) longevity biotech pursuing cellular rejuvenation programming. Relevant peer in the longevity biotech category and in its pursuit of epigenetic and cellular reprogramming approaches to healthspan extension.
  • Insilico Medicine: AI-driven longevity and drug discovery biotech with a pipeline of aging-related therapeutics. Comparable in pursuing technology-enabled longevity interventions, though focused on pharmaceutical rather than consumer delivery formats.
  • Turn Biotechnologies: US-based cellular rejuvenation company developing mRNA-based epigenetic reprogramming therapies. Directly comparable technology platform (epigenetic reprogramming) and overlap with regenerative medicine and exosome-adjacent delivery science.
  • ExoCoBio: South Korea-based exosome therapeutics and cosmetic company. Closest direct peer in commercializing exosome-derived products for regenerative and cosmetic applications in the Asian market.
  • Loyal for Dogs: Veterinary longevity biotech developing drugs to extend dog healthspan, with FDA engagement. Comparable in its science-driven, regulator-engaged approach to commercializing longevity interventions, though in the veterinary category.

Others

  • Good Hero Therapeutics: Tokyo-based gene therapy company and direct joint patent partner with Regenesome on ergothioneine-based AAV productivity enhancement. Closely tied via co-developed IP and capital/business alliance, making it a meaningful ecosystem participant rather than a competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Regenesome financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Regenesome leadership team

Management profile

Number of profiles

Profiles2 records

Regenesome funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Regenesome M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regenesome

What does Regenesome do?

Regenesome (リジェネソーム株式会社) is a longevity biotechnology venture that develops exosome-based supplements, foods, and cosmetics for anti-aging applications, combined with proprietary nanoparticle technology (Vicell for brain-targeted delivery, sake-derived nanoparticles for immune cell activation) and hypoxic environment technology. The company also conducts research into viral vector productivity enhancement for gene therapy manufacturing and offers consulting and intellectual property management services in longevity biotechnology.

Is Regenesome a public or private company?

Regenesome is a private company. It is classified as corporate owned and is currently operating.

When was Regenesome founded?

Regenesome was founded in 2024. It employs 1 to 10 people.

Where is Regenesome based?

Regenesome is headquartered in Tokyo, Japan, in the Asia region.

How does Regenesome make money?

Three revenue lines are on record. Exosome-based Products are the primary driver. The others are licensing and IP Management and consulting Services.

Who are Regenesome's main competitors?

Euglena Co., Ltd. is listed as a direct peer. Broad incumbents are Elysium Health, Calico Life Sciences and Unity Biotechnology. Emerging players are Altos Labs, Insilico Medicine, Turn Biotechnologies, ExoCoBio and Loyal for Dogs. Good Hero Therapeutics is listed as an others.

Does Regenesome have an API?

No public API is recorded for Regenesome.

What industry is Regenesome in?

Regenesome's product category is Longevity Biotechnology. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics). Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesSelecting, observing, and collecting exosomes from a 1mL sample - Joint patent application by Yodaka Giken and microfluidic technology.Space Seed Holdings, Regeneosome, and Yodaka Giken filed a joint patent for a microfluidic device that extracts and detects exosomes from body fluids in a single channel. The device performs selection, on-site detection, and quality-controlled collection without external pumps, enabling compact analysis for space and point-of-care use.PrtimesRegenerosome, 2nd Anniversary - "Delivering regeneration with nanoparticles" The journey of 2 years and the vision for 2030 and 2040 are published on the special site.Regenerosome Inc. celebrated its 2nd anniversary on July 12, 2026, and launched a special site detailing its two-year journey and future vision. The company aims to demonstrate anti-aging technology extending healthy life expectancy by 2030 and provide lunar-surface technology by 2040. It has raised 800 million yen in pre-seed funding and filed patents for nanoparticle-based aging control.PrtimesTo commemorate the 2nd anniversary of Regeneosome, we will hold the 'Regeneosome Tech Forum 2026' to introduce the progress of our business related to longevity.Regenerative Solutions Inc. will hold its Regenerative Tech Forum 2026 on July 24, 2026, in Tokyo to mark its second anniversary. The event will report on two years of longevity research, introduce the Saisei Lab brand, and showcase AI-based drug delivery technology. Pre-registration is required via Peatix.PrtimesCreating 'AI researchers' that experiment in space / Joint application for two patents related to an autonomous experimental platform that connects observation, judgment, and operation by LLM.Space Seed Holdings and three subsidiaries filed two joint patents on June 10, 2026, for autonomous experimental devices using LLMs to control cell culture and scientific experiments. The patents cover integrated cell-experiment control and a higher-level module-integration system, aiming to enable autonomous labs in space with limited communication. The companies plan ground verification and future tests in simulated microgravity.Prtimesロンジェビティテックベンチャー『リジェネソーム』、「GATEWAY Tech TAKANAWA 2026」に出展 脳に届けるナノ粒子の開発状況を紹介Regeneosome Inc. exhibited at TAKANAWA GATEWAY 2026 on May 13-14, 2026, introducing nanoparticles for brain delivery and low-oxygen longevity. The company, part of Space Seed Holdings, will open a Takanawa Longevity Lab in May 2025 to accelerate research.PrtimesHolding the Regenerative Medicine Tech Forum 2026 - Reporting on business progress and longevity research strategies.Regenesome and Space Seed Holdings held their Tech Forum 2026 on April 23, 2026, in Tokyo, reporting business progress and research results. They presented a strategy targeting the brain for longevity research, using nanoparticles to overcome the blood-brain barrier. The event included guest speakers on neurotechnology and AI.The Japan TimesRegenesome Launches Joint Research with FastNeura, a University of Tokyo–Born Neurotech Startup, to Evaluate the Effects of Hypoxic Environments | The Japan TimesRegenesome Inc. has initiated a joint research project with FastNeura Inc. to evaluate the effects of hypoxic environments on cognitive function through electroencephalography (EEG) signal analysis. The study aims to scientifically demonstrate these effects, potentially applying the findings to wellness and cognitive enhancement programs. This collaboration integrates advanced technologies from both companies, focusing on next-generation brain function regeneration solutions.PrtimesRegenesome raised 20 million yen through J-KISS type stock acquisition rights from Rivaness Capital.Regeneosome Inc. raised 20 million yen through J-KISS type stock acquisition rights with Livness Capital as underwriter in August 2025. The funds will accelerate joint research and development of anti-aging technologies, including the epigenetic clock and SAISEI supplements. A Series A round is planned after October 2025.PrtimesThe exosome research bio-venture 'Regenesome' has raised a total of 800 million yen in funding during its pre-seed round.Regeneosome Inc., a biotech startup focused on exosome-based anti-aging technologies, has secured 800 million yen in pre-seed funding. Japan System Technology Co., Ltd. acted as the underwriter for this investment round through the issuance of stock acquisition rights. The funds will support proof-of-concept studies aimed at developing applications for space medicine and terrestrial healthspan extension.